Figure 6 | Scientific Reports

Figure 6

From: Development of latent Interferon alpha 2b as a safe therapeutic for treatment of Hepatitis C virus infection

Figure 6

SDS-PAGE analysis and western blotting of purified fusion proteins under reducing and non-reducing conditions. (A) SDS-PAGE analysis of purified fusion proteins. Lane M: Protein size marker, Lane 1 & 2: purified IFNα2b-NS3-LAP and LAP-NS3-IFNα2b fusion proteins analyzed under non-reducing conditions (93.2 kDa band indicated by arrow). Lane 3 & 4: purified IFNα2b-NS3-LAP and LAP-NS3-IFNα2b fusion proteins respectively analyzed under reducing conditions (46.6 kDa band indicated by arrow). (B) Western blot analysis of purified proteins. Homodimers of IFNα2b-NS3-LAP and LAP-NS3-IFNα2b detected by mouse anti-human IFNα2 antibodies (blot 1 & 2) and by mouse anti-human LAP antibodies (blot 3 & 4). IFNα2b-NS3-LAP and LAP-NS3-IFNα2b detected with mouse anti-human IFNα2 antibodies (blot 5 & 6) and by mouse anti-human LAP antibodies (blot 7 & 8) by western blot under reducing conditions. (The resultant image of western blots is a product of time-averaged data). The full-length blots are presented in Supplementary Figs 13.

Back to article page